Based in the Department of Pathology and Laboratory Medicine, over the last 20 years the Loda Lab has studied the metabolic alterations that drive prostate tumorigenesis, with a specific interest in lipid metabolism. In 2004, Dr. Loda and his colleagues discovered a post-translational mechanism of regulation of fatty acid synthase (FASN), a key enzyme in lipid metabolism. After this seminal discovery, the Loda Lab has developed in vitro and in vivo models, lipidomics pipelines and phase I/II clinical trials to further test the interplay between FASN, lipids and prostate cancer, with the final aim to refine the currently available therapies to treat advanced prostate cancer.
Over the last years, the Loda Lab has also studied the complex interplay between tumor microenvironment and prostate cancer cells, with a particular focus on the prostate stroma. Combining the latest single-cell sequencing technologies, multiparametric image techniques, genetically engineered murine models and patient-derived specimens, Dr. Loda and colleagues have invented and perfectioned novel molecular pathology techniques to disentangle the complex crosstalk between stroma and prostate cancer cells.
The Loda Lab is also part of the Meyer Cancer Center, a multidisciplinary research enterprise with nearly 250 basic, translational, and clinical researchers who work together to achieve groundbreaking discoveries in cancer biology, and bring them from bench to bedside, and back again.
We welcome collaboration with other labs and investigators that seek to better understand the role of lipid metabolism and stroma in prostate cancer pathobiology.
Job Opportunities
Click here to view current job opportunities in the Loda Lab, and join us in NYC!